Furthermore, vigilin levels corelate with lipid accumulation in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, and knockdown of vigilin in liver reduces atherosclerotic plaque formation in mice suggesting an important role of vigilin in liver metabolism (49). Here, HDLBP is linked to metabolic dysfunction-associated steatohepatitis.